Neuroendocrinology of obesity

British Medical Bulletin

Volumn 109, Issue 1, 2014, Pages 73-82

  Field, Benjamin C T ^a,b  

^a SURREY AND SUSSEX HEALTHCARE NHS TRUST   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

gut hormone; obesity; therapy

Indexed keywords

AMYLIN; CHOLECYSTOKININ; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PEPTIDE YY [3-36]; PRAMLINTIDE;

ARTICLE; BARIATRIC SURGERY; CALORIC RESTRICTION; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS; ENERGY EXPENDITURE; HORMONE RELEASE; HUMAN; INSULIN RELEASE; NEUROENDOCRINOLOGY; NONHUMAN; NUTRITIONAL STATUS; OBESITY; PRIORITY JOURNAL; REMISSION; WEIGHT REDUCTION; ANOREXIA; APPETITE; DRUG SAFETY; FOOD INTAKE; HORMONE ACTION; HORMONE BLOOD LEVEL; PARABIOSIS; REVIEW;

GUT HORMONE; OBESITY; THERAPY;

BRAIN; GASTROINTESTINAL HORMONES; HUMANS; OBESITY;

EID: 84895898289     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldu001     Document Type: Article

References (43)

1. Haslam DW, James WPT. Obesity. Lancet 2005; 366:1197-209.
2. Morton GJ, Cummings DE, Baskin DG, et al. Central nervous system control of food intake and body weight. Nature 2006;443:289-95.
3. Hervey GR. The effects of lesions in the hypothalamus in parabiotic rats. J Physiol 1959;145:336-52.
4. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978;14:141-8.
5. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-32.
6. Halaas JL, Gajiwala KS, Maffei M, et al. Weightreducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-6.
7. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-84.
8. Asakawa A, Inui A, Yuzuriha H, et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 2003;124:1325-36.
9. Berntson GG, Zipf WB, O'Dorisio TM, et al. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 1993;14:497-503.
10. Batterham RL, le Roux CW, Cohen MA, et al. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003;88:3989-92.
11. Tan TM, Field BCT, Minnion JS, et al. Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 2012;73:232-9.
12. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-95.
13. Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009;17:1736-43.
14. Alford FP, Bloom SR, Nabarro JDN, et al. Glucagon control of fasting glucose in man. Lancet 1974;304: 974-7.
15. Schulman JL, Carleton JL, Whitney G, et al. Effect of glucagon on food intake and body weight in man. J Appl Physiol 1957;11:419-21.
16. Geething NC, To W, Spink BJ, et al. Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. PLoS ONE 2010;5:e10175.
17. Cummings DE, Frayo RS, Marmonier C, et al. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time-and food-related cues. Am J Physiol Endocrinol Metab 2004;287: E297-304.
18. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992-5.
19. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008;149:601-11.
20. Helmling S, Maasch C, Eulberg D, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. ProcNatl Acad Sci USA 2004;101:13174-9.
21. Shearman LP, Wang S-P, Helmling S, et al. Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006;147: 1517-26.
22. West DB, Fey D,Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol Regul Integr Comp Physiol 1984;246: R776-87.
23. Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 2008;83:281-7.
24. Kreymann B, Williams G, Ghatei MA, et al. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet 1987;330:1300-4.
25. Nauck MA, Heimesaat MM, Ørskov C, et al. Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-7.
26. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.
27. ZanderM,Madsbad S,Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30.
28. Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 2012;55:2343-7.
29. Dehmlow H, Alvarez Sánchez R, Bachmann S, et al. Discovery and optimisation of 1-hydroxyimino-3,3-diphenylpropanes, a new class of orally active GPBAR1 (TGR5) agonists. Bioorg Med Chem Lett 2013;23: 4627-32.
30. le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007;246:780-5.
31. Nygaard R, Nielbo S, Schwartz TW, et al. The PP-fold solution structure of human polypeptide YY and human PYY3-36 as determined by NMR. Biochemistry 2006;45:8350-7.
32. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-8.
33. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-7.
34. Neary NM, Small CJ, Druce MR, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005;146:5120-7.
35. Field BCT, Wren AM, Peters V, et al. PYY3x36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 2010;59: 1635-9.
36. Bataille D, Gespach C, Coudray AM, et al. 'Enteroglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence for an 'oxyntomodulin' action. Biosci Rep 1981;1:151-5.
37. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005;54:2390-5.
38. Cohen MA, Ellis SM, le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003;88:4696-701.
39. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 2006;30:1729-36.
40. Tan TM, Field BCT, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013;62:1131-8.
41. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009;58:2258-66.
42. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749-57.
43. Gingell JJ, Burns ER, Hay DL. Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors. Endocrinology 2014;155:21-6.